JP2021061848A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021061848A5 JP2021061848A5 JP2020218641A JP2020218641A JP2021061848A5 JP 2021061848 A5 JP2021061848 A5 JP 2021061848A5 JP 2020218641 A JP2020218641 A JP 2020218641A JP 2020218641 A JP2020218641 A JP 2020218641A JP 2021061848 A5 JP2021061848 A5 JP 2021061848A5
- Authority
- JP
- Japan
- Prior art keywords
- cytomegalovirus
- glycoprotein
- arenavirus
- nucleotide sequence
- protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000003886 Glycoproteins Human genes 0.000 claims 41
- 108090000288 Glycoproteins Proteins 0.000 claims 41
- 241000701022 Cytomegalovirus Species 0.000 claims 30
- 241000712891 Arenavirus Species 0.000 claims 25
- 239000002773 nucleotide Substances 0.000 claims 21
- 125000003729 nucleotide group Chemical group 0.000 claims 21
- 125000003275 alpha amino acid group Chemical group 0.000 claims 12
- 102000004169 proteins and genes Human genes 0.000 claims 11
- 108090000623 proteins and genes Proteins 0.000 claims 11
- 108700026244 Open Reading Frames Proteins 0.000 claims 10
- 230000001086 cytosolic effect Effects 0.000 claims 9
- 239000013603 viral vector Substances 0.000 claims 8
- 230000000890 antigenic effect Effects 0.000 claims 6
- 239000012634 fragment Substances 0.000 claims 6
- 208000015181 infectious disease Diseases 0.000 claims 6
- 230000002458 infectious effect Effects 0.000 claims 6
- 230000011218 segmentation Effects 0.000 claims 6
- 241000712899 Lymphocytic choriomeningitis mammarenavirus Species 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 239000013598 vector Substances 0.000 claims 4
- 230000002950 deficient Effects 0.000 claims 3
- 230000037430 deletion Effects 0.000 claims 3
- 238000012217 deletion Methods 0.000 claims 3
- 230000002068 genetic effect Effects 0.000 claims 3
- 239000002245 particle Substances 0.000 claims 3
- 230000010076 replication Effects 0.000 claims 3
- 206010010430 Congenital cytomegalovirus infection Diseases 0.000 claims 2
- 206010011831 Cytomegalovirus infection Diseases 0.000 claims 2
- 241000700605 Viruses Species 0.000 claims 2
- 239000000427 antigen Substances 0.000 claims 2
- 102000036639 antigens Human genes 0.000 claims 2
- 108091007433 antigens Proteins 0.000 claims 2
- 230000028993 immune response Effects 0.000 claims 2
- 238000010255 intramuscular injection Methods 0.000 claims 2
- 239000007927 intramuscular injection Substances 0.000 claims 2
- 230000005923 long-lasting effect Effects 0.000 claims 2
- 230000000527 lymphocytic effect Effects 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 101710186352 Probable membrane antigen 3 Proteins 0.000 claims 1
- 101710181078 Probable membrane antigen 75 Proteins 0.000 claims 1
- 101710178472 Tegument protein Proteins 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 230000035772 mutation Effects 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 150000007523 nucleic acids Chemical class 0.000 claims 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361911135P | 2013-12-03 | 2013-12-03 | |
| US61/911,135 | 2013-12-03 | ||
| US201462055699P | 2014-09-26 | 2014-09-26 | |
| US62/055,699 | 2014-09-26 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016536893A Division JP6818551B2 (ja) | 2013-12-03 | 2014-12-03 | Ｃｍｖワクチン |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021061848A JP2021061848A (ja) | 2021-04-22 |
| JP2021061848A5 true JP2021061848A5 (enExample) | 2021-07-26 |
| JP7001807B2 JP7001807B2 (ja) | 2022-02-04 |
Family
ID=52232138
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016536893A Active JP6818551B2 (ja) | 2013-12-03 | 2014-12-03 | Ｃｍｖワクチン |
| JP2020218641A Active JP7001807B2 (ja) | 2013-12-03 | 2020-12-28 | Ｃｍｖワクチン |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016536893A Active JP6818551B2 (ja) | 2013-12-03 | 2014-12-03 | Ｃｍｖワクチン |
Country Status (17)
| Country | Link |
|---|---|
| US (3) | US10111945B2 (enExample) |
| EP (2) | EP3077519B1 (enExample) |
| JP (2) | JP6818551B2 (enExample) |
| CN (2) | CN105980570B (enExample) |
| AU (2) | AU2014359276B2 (enExample) |
| CA (1) | CA2932318C (enExample) |
| CY (1) | CY1124288T1 (enExample) |
| DK (1) | DK3077519T3 (enExample) |
| ES (1) | ES2868427T3 (enExample) |
| HR (1) | HRP20211015T1 (enExample) |
| HU (1) | HUE054579T2 (enExample) |
| LT (1) | LT3077519T (enExample) |
| PL (1) | PL3077519T3 (enExample) |
| PT (1) | PT3077519T (enExample) |
| RS (1) | RS61993B1 (enExample) |
| SI (1) | SI3077519T1 (enExample) |
| WO (1) | WO2015082570A1 (enExample) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20221475T3 (hr) | 2007-12-27 | 2023-01-06 | Universität Zürich | Replikacijski defektni vektori arenavirusa |
| WO2015048744A2 (en) | 2013-09-30 | 2015-04-02 | Moderna Therapeutics, Inc. | Polynucleotides encoding immune modulating polypeptides |
| HRP20211015T1 (hr) * | 2013-12-03 | 2021-10-01 | Hookipa Biotech Gmbh | Cjepivo protiv citomegalovirusa (cmv) |
| EP3218504B1 (en) | 2014-11-13 | 2020-07-22 | Université de Genève | Tri-segmented arenaviruses as vaccine vectors |
| EP3031822A1 (en) * | 2014-12-08 | 2016-06-15 | Novartis AG | Cytomegalovirus antigens |
| HK1246183A1 (zh) | 2015-06-10 | 2018-09-07 | Hookipa Biotech Gmbh | Hpv疫苗 |
| CA3002922A1 (en) | 2015-10-22 | 2017-04-27 | Modernatx, Inc. | Human cytomegalovirus vaccine |
| SI3371316T1 (sl) * | 2015-11-04 | 2023-02-28 | Hookipa Biotech Gmbh | Cepivo proti virusu hepatitisa B |
| WO2017080920A1 (en) * | 2015-11-12 | 2017-05-18 | Hookipa Biotech Ag | Arenavirus particles as cancer vaccines |
| US11260090B2 (en) | 2016-03-08 | 2022-03-01 | University Of Vermont And State Agricultural College | Modified arenavirus |
| IL262207B1 (en) | 2016-04-15 | 2025-09-01 | Univ Pennsylvania | Compositions for treatment of wet age-related macular degeneration |
| WO2018075980A1 (en) * | 2016-10-21 | 2018-04-26 | Modernatx, Inc. | Human cytomegalovirus vaccine |
| CN110167586B (zh) | 2016-11-04 | 2024-01-30 | 霍欧奇帕生物科技有限公司 | 作为癌症疫苗的复制-缺陷型沙粒病毒颗粒和三-节段沙粒病毒颗粒 |
| TW202532642A (zh) | 2017-04-14 | 2025-08-16 | 美商銳進科斯生物股份有限公司 | 使用由人類神經或膠細胞產生的重組人類艾杜糖醛酸鹽 (iduronate)-2-硫酸酯酶 (ids) 之黏多醣病ii之治療 |
| WO2018204080A1 (en) * | 2017-05-02 | 2018-11-08 | The Scripps Research Institute | Compositions and methods related to arenavirus immunogens |
| JP2021535730A (ja) * | 2018-05-11 | 2021-12-23 | シティ・オブ・ホープCity of Hope | 複数の部位メガロウイルス（ｃｍｖ）抗原の発現のためのｍｖａベクター及びその使用 |
| MX2021004273A (es) | 2018-10-17 | 2021-12-10 | Glaxosmithkline Biologicals Sa | Proteinas de citomegalovirus modificadas y complejos estabilizados. |
| EP3895730A4 (en) | 2018-12-10 | 2022-10-19 | KM Biologics Co., Ltd. | VACCINE FOR THE PREVENTION OR TREATMENT OF CONGENITAL CYTOMEGALOVIRUS INFECTION |
| AU2020377504A1 (en) * | 2019-11-07 | 2022-06-02 | Universität Basel | Arenaviruses as vectors |
| WO2021251384A1 (ja) * | 2020-06-09 | 2021-12-16 | Ｋｍバイオロジクス株式会社 | サイトメガロウイルスのｇＢとペンタマーとの融合タンパク質及び該融合タンパク質を含むワクチン |
| US11406703B2 (en) | 2020-08-25 | 2022-08-09 | Modernatx, Inc. | Human cytomegalovirus vaccine |
| RU2756557C1 (ru) * | 2020-11-02 | 2021-10-01 | Федеральное государственное бюджетное учреждение "Федеральный центр охраны здоровья животных" (ФГБУ "ВНИИЗЖ") | Способ опосредованного определения титра вируса ящура в неинактивированном сырье для вакцины при амплификации вирусной нуклеиновой кислоты и детекции РНК-ампликонов с применением технологии молекулярных биконов |
| EP4291249A2 (en) | 2021-02-10 | 2023-12-20 | RegenxBio Inc. | Treatment of mucopolysaccharidosis ii with recombinant human iduronate-2-sulfatase (ids) |
| WO2022238546A1 (en) | 2021-05-13 | 2022-11-17 | Hookipa Biotech Gmbh | Arenaviruses as vectors |
| WO2024163912A2 (en) * | 2023-02-03 | 2024-08-08 | The Children's Medical Center Corporation | Vaccine and therapeutic protein delivery compositions comprising fusion proteins |
| WO2025056782A1 (en) | 2023-09-15 | 2025-03-20 | Hookipa Biotech Gmbh | Arenavirus formulations, methods and uses thereof |
| CN118221773B (zh) * | 2024-02-05 | 2025-09-09 | 首都医科大学附属北京儿童医院保定医院 | 与HLA相关的CMV pp65表位疫苗组合物与应用 |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5057540A (en) | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
| DE68929478T2 (de) * | 1988-01-29 | 2004-04-29 | Aventis Pasteur | Rekombinante CMV-Neutralisierungsproteine |
| US4912094B1 (en) | 1988-06-29 | 1994-02-15 | Ribi Immunochem Research Inc. | Modified lipopolysaccharides and process of preparation |
| CA2403681A1 (en) * | 2000-03-21 | 2001-09-27 | Genzyme Corporation | Therapeutic anti-cytomegalovirus compounds |
| DE102004034461B4 (de) * | 2004-07-16 | 2008-02-07 | Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus | Gentherapie solider Tumore durch retrovirale, mit Arenavirus-Glykoprotein pseudotypisierte Vektoren |
| CA2597921A1 (en) * | 2005-02-15 | 2007-04-26 | University Of North Carolina At Chapel Hill | New live virus vaccines |
| ATE539079T1 (de) | 2006-03-23 | 2012-01-15 | Novartis Ag | Imidazochinoxalinverbindungen als immunmodulatoren |
| WO2007109812A2 (en) | 2006-03-23 | 2007-09-27 | Novartis Ag | Immunopotentiating compounds |
| HRP20221475T3 (hr) | 2007-12-27 | 2023-01-06 | Universität Zürich | Replikacijski defektni vektori arenavirusa |
| US8580276B2 (en) * | 2009-06-05 | 2013-11-12 | City Of Hope | Genetically stable recombinant modified vaccinia ankara (rMVA) vaccines and methods of preparation thereof |
| WO2010148541A1 (zh) * | 2009-06-26 | 2010-12-29 | 鑫品生医科技股份有限公司 | 含衍生自细胞巨大病毒的胜肽的免疫原组成物及使用方法 |
| JP6138047B2 (ja) * | 2010-10-15 | 2017-05-31 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | サイトメガロウイルスｇＢ抗原 |
| JP2014502848A (ja) * | 2011-01-07 | 2014-02-06 | バイオサイエンス・スロバキア | ウイルス診断 |
| WO2012162428A1 (en) * | 2011-05-23 | 2012-11-29 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Prime-boost vaccination for viral infection |
| EP2729165B1 (en) * | 2011-07-06 | 2017-11-08 | GlaxoSmithKline Biologicals SA | Immunogenic combination compositions and uses thereof |
| US8834307B2 (en) | 2011-10-06 | 2014-09-16 | Kawasaki Jukogyo Kabushiki Kaisha | Belt type continuously variable transmission |
| EP2766385A2 (en) * | 2011-10-12 | 2014-08-20 | Novartis AG | Cmv antigens and uses thereof |
| ES2753138T3 (es) * | 2012-07-06 | 2020-04-07 | Glaxosmithkline Biologicals Sa | Complejos de proteínas de citomegalovirus |
| US9809801B2 (en) | 2013-03-15 | 2017-11-07 | Université De Genève | Anti-mycobacterial vaccines |
| HRP20211015T1 (hr) | 2013-12-03 | 2021-10-01 | Hookipa Biotech Gmbh | Cjepivo protiv citomegalovirusa (cmv) |
| EP3218504B1 (en) * | 2014-11-13 | 2020-07-22 | Université de Genève | Tri-segmented arenaviruses as vaccine vectors |
| HK1246183A1 (zh) | 2015-06-10 | 2018-09-07 | Hookipa Biotech Gmbh | Hpv疫苗 |
| SI3371316T1 (sl) | 2015-11-04 | 2023-02-28 | Hookipa Biotech Gmbh | Cepivo proti virusu hepatitisa B |
| WO2017080920A1 (en) | 2015-11-12 | 2017-05-18 | Hookipa Biotech Ag | Arenavirus particles as cancer vaccines |
| KR20240095333A (ko) | 2016-05-18 | 2024-06-25 | 유니버시타트 바셀 | 백신 벡터로서 3개의 세그먼트를 가진 피친드 바이러스 |
| CN110167586B (zh) | 2016-11-04 | 2024-01-30 | 霍欧奇帕生物科技有限公司 | 作为癌症疫苗的复制-缺陷型沙粒病毒颗粒和三-节段沙粒病毒颗粒 |
| JP2020516601A (ja) | 2017-04-07 | 2020-06-11 | ホオキパ バイオテック ジーエムビーエイチ | 固形腫瘍を治療するためのアレナウイルス粒子 |
| AU2020377504A1 (en) | 2019-11-07 | 2022-06-02 | Universität Basel | Arenaviruses as vectors |
| AU2021282287A1 (en) | 2020-05-29 | 2023-01-05 | Hookipa Biotech Gmbh | Cancer treatment strategies using arenavirus vectors |
-
2014
- 2014-12-03 HR HRP20211015TT patent/HRP20211015T1/hr unknown
- 2014-12-03 CN CN201480074709.4A patent/CN105980570B/zh active Active
- 2014-12-03 EP EP14820762.4A patent/EP3077519B1/en active Active
- 2014-12-03 PT PT148207624T patent/PT3077519T/pt unknown
- 2014-12-03 HU HUE14820762A patent/HUE054579T2/hu unknown
- 2014-12-03 ES ES14820762T patent/ES2868427T3/es active Active
- 2014-12-03 CA CA2932318A patent/CA2932318C/en active Active
- 2014-12-03 LT LTEP14820762.4T patent/LT3077519T/lt unknown
- 2014-12-03 AU AU2014359276A patent/AU2014359276B2/en active Active
- 2014-12-03 US US15/101,363 patent/US10111945B2/en active Active
- 2014-12-03 PL PL14820762T patent/PL3077519T3/pl unknown
- 2014-12-03 EP EP21165671.5A patent/EP3904522A1/en not_active Withdrawn
- 2014-12-03 DK DK14820762.4T patent/DK3077519T3/da active
- 2014-12-03 SI SI201431830T patent/SI3077519T1/sl unknown
- 2014-12-03 JP JP2016536893A patent/JP6818551B2/ja active Active
- 2014-12-03 RS RS20210759A patent/RS61993B1/sr unknown
- 2014-12-03 WO PCT/EP2014/076466 patent/WO2015082570A1/en not_active Ceased
- 2014-12-03 CN CN202210602284.6A patent/CN115058452A/zh active Pending
-
2018
- 2018-09-20 US US16/137,323 patent/US11554169B2/en active Active
-
2020
- 2020-12-28 JP JP2020218641A patent/JP7001807B2/ja active Active
-
2021
- 2021-04-26 AU AU2021202541A patent/AU2021202541A1/en not_active Abandoned
- 2021-06-29 CY CY20211100578T patent/CY1124288T1/el unknown
-
2022
- 2022-11-22 US US18/058,116 patent/US20230181725A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021061848A5 (enExample) | ||
| HRP20211015T1 (hr) | Cjepivo protiv citomegalovirusa (cmv) | |
| Tsai et al. | Complete genome sequence of the grouper iridovirus and comparison of genomic organization with those of other iridoviruses | |
| JP2021182922A5 (enExample) | ||
| JP2017503482A5 (enExample) | ||
| Havenga et al. | Novel replication-incompetent adenoviral B-group vectors: high vector stability and yield in PER. C6 cells | |
| Lewis et al. | An African swine fever virus ERV1-ALR homologue, 9GL, affects virion maturation and viral growth in macrophages and viral virulence in swine | |
| Smith et al. | Laboratory strains of murine cytomegalovirus are genetically similar to but phenotypically distinct from wild strains of virus | |
| Tsai et al. | Spontaneous lytic replication and epitheliotropism define an Epstein-Barr virus strain found in carcinomas | |
| Song et al. | Functional genomics analysis of Singapore grouper iridovirus: complete sequence determination and proteomic analysis | |
| Ruiss et al. | A virus-like particle-based Epstein-Barr virus vaccine | |
| Drillien et al. | Modified vaccinia virus Ankara induces moderate activation of human dendritic cells | |
| Verardi et al. | Vaccinia virus vectors with an inactivated gamma interferon receptor homolog gene (B8R) are attenuated in vivo without a concomitant reduction in immunogenicity | |
| FI3371316T3 (fi) | Rokotteita hepatiitti b -virusta vastaan | |
| JP2018536433A5 (enExample) | ||
| Wang et al. | Recoding of the vesicular stomatitis virus L gene by computer-aided design provides a live, attenuated vaccine candidate | |
| Fleming et al. | Genomic analysis of a transposition-deletion variant of orf virus reveals a 3.3 kbp region of non-essential DNA | |
| Kerr et al. | Genome scale evolution of myxoma virus reveals host-pathogen adaptation and rapid geographic spread | |
| Niizuma et al. | Construction of varicella-zoster virus recombinants from parent Oka cosmids and demonstration that ORF65 protein is dispensable for infection of human skin and T cells in the SCID-hu mouse model | |
| Rouxel et al. | Attenuated infectious hematopoietic necrosis virus with rearranged gene order as potential vaccine | |
| Clambey et al. | Characterization of a spontaneous 9.5-kilobase-deletion mutant of murine gammaherpesvirus 68 reveals tissue-specific genetic requirements for latency | |
| Liang et al. | Biological characteristics, biosafety prevention and control strategies for the 2022 multi-country outbreak of monkeypox | |
| McVoy et al. | Repair of a mutation disrupting the guinea pig cytomegalovirus pentameric complex acquired during fibroblast passage restores pathogenesis in immune-suppressed guinea pigs and in the context of congenital infection | |
| Sakala et al. | Poxvirus-encoded gamma interferon binding protein dampens the host immune response to infection | |
| Hughes et al. | Characterization of a novel wood mouse virus related to murid herpesvirus 4 |